Table 1.
Patient characteristics
| Responders | Non-responders | |
|---|---|---|
| Patients | ||
| N | 11 | 6 |
| Age | ||
| Median | 71.0 (66–84) | 62.5 (53–78) |
| Sex | ||
| Female | 5 (45%) | 2 (33%) |
| Male | 6 (55%) | 4 (67%) |
| Metastasis | ||
| M1a | 4 (36%) | – |
| M1b | 3 (27%) | 1 (17%) |
| M1c | 4 (36%) | 5 (83%) |
| BRAFV600 | ||
| Mutated | 1 (17%) | 3 (50%) |
| No mutation | 10 (83%) | 3 (50%) |
| PreLDH | ||
| Median | 240.0 Ul (159–357) | 226.5 Ul (180–411) |
| Drug | ||
| Nivolumab | 4 (36%) | 3 (50%) |
| Pembrolizumab | 7 (64%) | 3 (50%) |
| Follow-up time | ||
| Median | 21.0 months (12–27) | 21.0 months (12–27) |
| PFS | ||
| Median | 12.0 months (3–20) | 3.0 months (1–6) |
| Best response | ||
| CR | 2 (18%) | – |
| PR | 5 (45%) | – |
| SD | 4 (36%) | 1 (17%) |
| PD | – | 5 (83%) |
M1a metastasis in distant skin sites or areas under the skin or in distant lymph nodes with normal LDH, M1b metastasis in lung with normal LDH levels, M1c metastasis in internal organ or any other metastasis with elevated LDH. Best achieved response during anti-PD1 therapy: CR complete response, PR partial response, SD stable disease, PD progressive disease